Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

Source: Immuno-Oncology, February 2021

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release.

The breakthrough therapy status was awarded after a Phase 3 trial showed that tebentafusp worked better than currently available treatments in extending survival in certain newly diagnosed uveal melanoma patients.

READ THE ORIGINAL FULL ARTICLE